• Pfizer (NYSE:PFE) plans to unveil major oncology pipeline updates at the ASCO 2026 Annual Meeting.
• The company will present new clinical data across its cancer portfolio, including LORBRENA, BRAFTOVI, TALZENNA, and TUKYSA.
• Pfizer will also highlight early and late stage pipeline assets that expand its presence in multiple tumor types.

For investors tracking Pfizer, the ASCO 2026 update is an important moment in the company’s effort to reposition itself around oncology rather than COVID related products. The focus on marketed therapies such as LORBRENA, BRAFTOVI, TALZENNA, and TUKYSA, together with earlier pipeline candidates, provides a clearer view of how Pfizer is building depth across several cancer segments.

This breadth of oncology data may influence how investors think about Pfizer’s future product mix, revenue diversity, and research priorities. The event also offers another reference point for comparing Pfizer’s cancer portfolio with large pharma peers that are competing for share across targeted therapies, antibody based drugs, and combination regimens.

Stay updated on the most important news stories for Pfizer by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Pfizer.

The ASCO 2026 spotlight on Pfizer’s oncology pipeline comes on top of the Priority Review for PADCEV plus Keytruda in muscle invasive bladder cancer, which is backed by Phase 3 EV 304 data showing lower risks of recurrence and death versus standard chemotherapy. For you as an investor, that combination of near term regulatory catalysts and a broad set of readouts across LORBRENA, BRAFTOVI, TALZENNA and TUKYSA reinforces how much of Pfizer’s future story is tied to cancer care. Success here would deepen Pfizer’s presence in solid tumors where Merck, Bristol Myers Squibb and AstraZeneca are also heavily invested, and could support a more oncology weighted revenue mix over time compared with the company’s COVID period profile.

How This Fits Into The Pfizer Narrative

• The PADCEV plus Keytruda program and the wider ASCO oncology updates align with the narrative that Pfizer is leaning on late stage cancer assets and biologics to offset patent pressures and past COVID revenue.
• Execution risk around regulatory decisions, competition from other large pharma companies and the need to convert early stage assets into commercial products may challenge the view that oncology alone can comfortably cover patent expirations and pricing pressure.
• The perioperative use of PADCEV plus Keytruda in earlier stage bladder cancer and the specific trial results in EV 304 may not be fully reflected in high level narrative themes that focus more broadly on oncology and emerging markets.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Pfizer to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts highlight that earnings are expected to decline by an average of 2.9% a year over the next 3 years, so oncology progress still sits against a weaker earnings profile.
• ⚠️ Dividend payments around 6.3% are not well covered by earnings or free cash flow and debt coverage by operating cash flow is also flagged, which can limit how much capital Pfizer can commit to new oncology projects.
• 🎁 The PADCEV plus Keytruda data in muscle invasive bladder cancer, together with multiple oncology readouts at ASCO 2026, gives Pfizer more ways to participate in cancer segments where treatment needs remain high.
• 🎁 Simply Wall St’s models currently see Pfizer trading at a large discount to estimated fair value, so positive oncology and regulatory milestones could be important catalysts if sentiment starts to reflect those assets more fully.

What To Watch Going Forward

From here, keep an eye on the FDA’s August 17, 2026 target decision date for the PADCEV plus Keytruda perioperative sBLA, label wording around cisplatin eligible and ineligible patients, and any new ASCO data that shifts how Pfizer’s drugs are used relative to Merck’s Keytruda monotherapy and other standard regimens. Also watch how quickly Pfizer can turn next generation assets and combinations into late stage programs that support its broader reset away from COVID revenue and toward oncology, obesity and vaccines.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Pfizer, head to the community page for Pfizer to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.